Press Releases Cynapsus Therapeutics Inc

Equities

CTH

CA23257Y8595

Delayed Toronto S.E. Other stock markets			5-day change	1st Jan Change
- ^CAD	-.--%		+0.21%	-.--%

11/03	Mkango and CoTec Brief: Mkango Subsidiary, Maginito, And CoTec Appointed Lead Engineers BBA And Pegasus To Complete Feasibility Study for HyProMag USA	MT
29/01	CoTec Holdings Outlines Key Targets For 2024	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cynapsus Therapeutics : Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics	01/16/01	PU
Cynapsus Therapeutics : Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease	29/16/29	GL
Cynapsus Therapeutics : Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson's Disease Clinical Study Allowing for At-Home Titration	15/16/15	GL
Cynapsus Therapeutics : Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease	12/16/12	GL
Cynapsus Therapeutics : Reports Second Quarter 2016 Financial Results and Recent Developments	11/16/11	GL
Cynapsus Therapeutics : Provides European Clinical Update for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease	19/16/19	GL
Cynapsus Therapeutics Provides European Clinical Update for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease	19/16/19	GL
Cynapsus Therapeutics : Announces Positive Phase 3 Dose Titration Phase Results with APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease	19/16/19	GL
Cynapsus Therapeutics : Announces 2016 Analyst and Investor Day	06/16/06	GL
Cynapsus Therapeutics Announces 2016 Analyst and Investor Day	06/16/06	GL
Cynapsus Therapeutics : Enrolls Last Patient in Pivotal Phase 3 Efficacy Trial of APL-130277 to Treat OFF Episodes in Patients with Parkinson's Disease	30/16/30	GL
Cynapsus Therapeutics Enrolls Last Patient in Pivotal Phase 3 Efficacy Trial of APL-130277 to Treat OFF Episodes in Patients with Parkinson’s Disease	30/16/30	GL
Cynapsus Therapeutics Announces Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders	21/16/21	GL
Cynapsus Therapeutics : Announces Data Presentations at the European Academy of Neurology Annual Meeting	30/16/30	GL
Cynapsus Therapeutics Announces Data Presentations at the European Academy of Neurology Annual Meeting	30/16/30	GL
Cynapsus Therapeutics Appoints Frederick Driscoll to Its Board of Directors	20/16/20	GL
Cynapsus Therapeutics Reports First Quarter 2016 Financial Results and Recent Developments	12/16/12	GL
Cynapsus Therapeutics Announces Results of AGM	12/16/12	GL
Cynapsus Therapeutics to Present at Several Upcoming Investor Conferences	28/16/28	GL
Cynapsus Therapeutics : Announces Data Presentations at the American Academy of Neurology Annual Meeting	15/16/15	MW

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cynapsus Therapeutics Inc

Equities

CTH

CA23257Y8595

Press Releases

Filters